Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Join this 47-minute webinar to explore the growing evidence supporting exercise as a crucial treatment component for adult patients with Idiopathic Inflammatory Myopathies (IIM). Learn from three leading experts who will present comprehensive insights on how to initiate and maintain exercise programs during IIM treatment.
Discover the latest research findings from Prof. Ingrid Lundberg, a rheumatology expert from Karolinska Institutet who specializes in translational myositis research combining exercise interventions with muscle biopsy investigations and immunological markers. Gain insights from Prof. Louise Diederichsen from Copenhagen University Hospital, whose research focuses on cardiac involvement, imaging, and physical exercise in myositis, including her work on Blood-Flow-Restriction training and high-intensity strength training studies. Explore evidence-based exercise approaches with Prof. Helene Alexanderson, a world-leading physical therapist and associate professor who has spent over 20 years investigating exercise effects in myositis patients, developing everything from basic exercise programs to high-intensity interval training protocols.
Understand the evolution of exercise therapy in myositis treatment, from initial cautious approaches to current evidence-based intensive training methods. Learn about practical implementation strategies for exercise programs in clinical practice, including patient assessment, program design, and monitoring techniques. Examine the physiological effects of different exercise modalities on muscle performance, tissue inflammation, and overall patient outcomes in IIM.
Access expert guidance on overcoming common challenges in prescribing exercise for myositis patients, including safety considerations, progression protocols, and patient-reported outcome measures. Benefit from the collective expertise of speakers who have contributed to international myositis research networks, clinical trials, and outcome measure development for this patient population.
